AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

9/29/25 4:05:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ABCL alert in real time by email

AbCellera (NASDAQ: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (NASDAQ: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250929862522/en/

Inquiries

Media: Tiffany Chiu; [email protected], +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005

Investor Relations: Peter Ahn; [email protected], +1(778)729-9116

Get the next $ABCL alert in real time by email

Recent Analyst Ratings for

$ABCL

Date	Price Target	Rating	Analyst
7/7/2025	$5.00	Outperform	Leerink Partners
8/20/2024		Buy → Hold	The Benchmark Company
2/22/2024	$9.00	Hold → Buy	The Benchmark Company
12/5/2023	$6.00	Overweight	KeyBanc Capital Markets
11/6/2023		Buy → Hold	The Benchmark Company
10/13/2023	$20.00	Overweight	Piper Sandler
2/28/2023		Outperform	Cowen
12/15/2022	$30.00	Buy	Goldman

More analyst ratings

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ABCL

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$ABCL

$ABCL
Insider Purchases

Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

$ABCL
Press Releases